OpGen: Edison Open House Healthcare 2022

OpGen: Edison Open House Healthcare 2022

OpGen — 5 videos in collection

More on this equity

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

• Tell us about OpGen’s focus on and approach to antimicrobial resistance.
• Please describe your licensing strategy for Ares Genetics.
• How large do you anticipate the unmet need in the genomic sequencing market to be?
• Which milestones should investors focus on in the coming year?

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free